Skip to main content
. 2017 Jun 21;134(3):459–473. doi: 10.1007/s00401-017-1738-2

Table 1.

Demographic and neuropathological characteristics of study cohort

AD Control Statistic(df), p value
Cohort number 27 28
Mean age, years (±SD) 84.01 (6.84) 84.04 (9.00) t (53) = 0.17, p = 0.987
Gender M:F 11:16 13:15 χ 2(1) = 0.181, p = 0.671
Mean PMD, hours (±SD) 51.53 (23.70) 53.00 (24.84) t (31) = 1.73, p = 0.864
Thal Aβ phase [57] Phase 4, n = 2
Phase 5, n = 25		 Phase 0, n = 8 Phase 1, n = 9 Phase 2, n = 5 Phase 3, n = 3
Phase 4, n = 2
Phase 5, n = 1		 U (53) = 16.5, p = 0.0001
Braak NFT stage [10] NFT stage 5, n = 3
NFT stage 6, n = 24		 NFT stage 0, n = 2 NFT stage 1, n = 3 NFT stage 2, n = 11 NFT stage 3, n = 11 NFT stage 4, n = 1 U (53) = 0.500, p = 0.0001
CERAD [43] C, n = 27 Negative, n = 23 A, n = 3 B, n = 2 –
NIA-AA [44] High, n = 27 No, n = 8
Low, n = 18 Intermediate, n = 2		 –
Braak LB stage [9] LFB stage 0, n = 25
LFB stage 1, n = 0
LFB stage 2, n = 1
LFB stage 3, n = 1		 LFB stage 0, n = 24
LFB stage 1, n = 1
LFB stage 2, n = 1
LFB stage 3, n = 2		 –
McKeith criteria [42] No LBD, n = 25
Amygdala predominant, n = 2		 No LBD, n = 24
Brainstem, n = 2
Amygdala predominant, n = 2		 –
VCING criteria [53] Low, n = 28 Low, n = 25
Moderate, n = 2		 –
TDP-43 in AD score [30] Stage 0, n = 12
Stage 1, n = 3
Stage 2, n = 4
Stage 3, n = 2
Stage 4, n = 6		 Stage 0, n = 21
Stage 1, n = 3
Stage 2, n = 1
Stage 3, n = 1
Stage 4, n = 2		 –
CAA score [46] Stage 0, n = 1
Stage 1, n = 3
Stage 2, n = 12
Stage 3, n = 9
Stage 4, n = 3
CapCAA absent, n = 1
CapCAA present, n = 26		 Stage 0, n = 15
Stage 1, n = 5
Stage 2, n = 8
CapCAA absent, n = 15
CapCAA present, n = 13		 –
MMSE (±SD) [19] 5.82 (5.36) 26 (4.34) t (21) = 8.269, p = 0.0001

AD Alzheimer’s disease, df degrees of freedom; t Independent samples test, X 2 Chi -squared test, F female, M Male, U Mann–Whitney U test, PMD post mortem delay, Aβ amyloid-beta, NFT neurofibrillary tangle, CERAD Consortium to Establish a Registry for Alzheimer’s Disease, NIA-AA National Institute on Ageing-Alzheimer’s Association criteria for AD neuropathologic change, LB Lewy body, VCING vascular cognitive impairment neuropathological guidelines, CAA cerebral amyloid angiopathy, CapCAA capillary CAA, MMSE mini mental state examination